Author:
O'Keeffe Serena,Fleming Cathy,Vintró Luis León,McClean Brendan
Reference13 articles.
1. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK’s largest cohort of lung SABR patients;Saha;Acta Oncol (Madr),2021
2. Hernandez V, et al., What is plan quality in radiotherapy? The importance of evaluating dose metrics, complexity, and robustness of treatment plans, Radiother Oncol, 2020;153:26–33, Dec. 01, 2020. doi: 10.1016/j.radonc.2020.09.038.
3. A single centre evaluation of the 2019 UK SABR consortium guidelines for primary lung cancer: correlation between Prescription Dose Spillage and inverse Paddick Conformity Index;Gray;Rep Pract Oncol Radiother,2022
4. Patel G, Mandal A, Choudhary S, Mishra R, Shende R, Plan evaluation indices: A journey of evolution,” Rep Pract Oncol Radiother, 2020;25(3):336–344. doi: 10.1016/j.rpor.2020.03.002.
5. “Stereotactic Ablative Body Radiation Therapy (SABR): A resource The Faculty of Clinical Oncology of The Royal College of Radiologists v6.1,”; 2019.